keyword
MENU ▼
Read by QxMD icon Read
search

Lung SBRT

keyword
https://www.readbyqxmd.com/read/29349867/volumetric-modulated-arc-therapy-treatment-planning-of-thoracic-vertebral-metastases-using-stereotactic-body-radiotherapy
#1
Matthew Mallory, Damodar Pokhrel, Rajeev Badkul, Hongyu Jiang, Christopher Lominska, Fen Wang
PURPOSE/OBJECTIVES: To retrospectively evaluate the plan quality, treatment efficiency, and accuracy of volumetric modulated arc therapy (VMAT) plans for thoracic spine metastases using stereotactic body radiotherapy (SBRT). MATERIALS/METHODS: Seven patients with thoracic vertebral metastases treated with noncoplanar hybrid arcs (NCHA) (1 to 2 3D-conformal partial arcs +7 to 9 IMRT beams) were re-optimized with VMAT plans using three coplanar arcs. Tumors were located between T2 and T7 and PTVs ranged between 24...
January 19, 2018: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/29346041/post-treatment-mortality-after-surgery-and-stereotactic-body-radiotherapy-for-early-stage-non-small-cell-lung-cancer
#2
William A Stokes, Michael R Bronsert, Robert A Meguid, Matthew G Blum, Bernard L Jones, Matthew Koshy, David J Sher, Alexander V Louie, David A Palma, Suresh Senan, Laurie E Gaspar, Brian D Kavanagh, Chad G Rusthoven
Purpose In early-stage non-small cell lung cancer (NSCLC), post-treatment mortality may influence the comparative effectiveness of surgery and stereotactic body radiotherapy (SBRT), with implications for shared decision making among high-risk surgical candidates. We analyzed early mortality after these interventions using the National Cancer Database. Patients and Methods We abstracted patients with cT1-T2a, N0, M0 NSCLC diagnosed between 2004 and 2013 undergoing either surgery or SBRT. Thirty-day and 90-day post-treatment mortality rates were calculated and compared using Cox regression and propensity score-matched analyses...
January 18, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29334910/treatment-selection-of-early-stage-non-small-cell-lung-cancer-the-role-of-the-patient-in-clinical-decision-making
#3
S Mokhles, J J M E Nuyttens, M de Mol, J G J V Aerts, A P W M Maat, Ö Birim, A J J C Bogers, J J M Takkenberg
BACKGROUND: The objective of this study is to investigate the role and experience of early stage non-small cell lung cancer (NSCLC) patient in decision making process concerning treatment selection in the current clinical practice. METHODS: Stage I-II NSCLC patients (surgery 55 patients, SBRT 29 patients, median age 68) were included in this prospective study and completed a questionnaire that explored: (1) perceived patient knowledge of the advantages and disadvantages of the treatment options, (2) experience with current clinical decision making, and (3) the information that the patient reported to have received from their treating physician...
January 15, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29332497/dosimetric-analysis-of-microscopic-disease-in-sbrt-for-lung-cancers
#4
Ronghu Mao, Lingling Tian, You Zhang, Lei Ren, Renqi Gao, Fang-Fang Yin, Hong Ge
OBJECTIVE: The objective of this study is to theoretically and experimentally evaluate the dosimetry in the microscopic disease regions surrounding the tumor under stereotactic body radiation therapy of lung cancer. METHODS: For simplicity, the tumor was considered moving along 1 dimension with a periodic function. The probability distribution function of the tumor position was generated according to the motion pattern and was used to estimate the delivered dose in the microscopic disease region...
December 2017: Technology in Cancer Research & Treatment
https://www.readbyqxmd.com/read/29331227/the-impact-of-technology-on-the-changing-practice-of-lung-sbrt
#5
REVIEW
Marianne Camille Aznar, Samantha Warren, Mischa Hoogeman, Mirjana Josipovic
Stereotactic body radiotherapy (SBRT) for lung tumours has been gaining wide acceptance in lung cancer. Here, we review the technological evolution of SBRT delivery in lung cancer, from the first treatments using the stereotactic body frame in the 1990's to modern developments in image guidance and motion management. Finally, we discuss the impact of current technological approaches on the requirements for quality assurance as well as future technological developments.
January 10, 2018: Physica Medica: PM
https://www.readbyqxmd.com/read/29327241/a-suvmax-based-propensity-matched-analysis-of-stereotactic-body-radiotherapy-versus-surgery-in-stage-i-non-small-cell-lung-cancer-unveiling-the-role-of-18f-fdg-pet-ct-in-clinical-decision-making
#6
L Ye, F Xu, S Shi, Z Zeng, X Jin, Y Huang, C Lu, J Gu, D Ge, J He
BACKGROUND: The value of maximum standard uptake value (SUVmax) was overlooked in current studies comparing stereotactic body radiotherapy (SBRT) versus surgery for stage I non-small cell lung cancer (NSCLC). Herein, we aimed to compare the 3-year outcomes based on patients for whom SUVmax were available, and to explore the role of SUVmax in clinical decision-making. METHODS: From January 2010 to June 2016, data of eligible patients were collected. Patient variables and clinical outcomes were compared in both unmatched and matched groups using propensity score matching (PSM)...
January 11, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29325801/editorial-the-role-of-medical-physics-in-lung-sbrt
#7
EDITORIAL
Pietro Mancosu, Andrew Nisbet, Núria Jornet
Stereotactic body radiation therapy (SBRT) has become a standard treatment for non-operable patients with early stage non-small cell lung cancer (NSCLC). In this context, medical physics community has largely helped in the starting and the growth of this technique. In fact, SBRT requires the convergence of many different features for delivering large doses in few fractions to small moving target in an heterogeneous medium. The special issue of last month, was focused on the different physics challenges in lung SBRT...
January 9, 2018: Physica Medica: PM
https://www.readbyqxmd.com/read/29312866/quantitative-texture-analysis-on-pre-treatment-computed-tomography-predicts-local-recurrence-in-stage-i-non-small-cell-lung-cancer-following-stereotactic-radiation-therapy
#8
Carole Dennie, Rebecca Thornhill, Carolina A Souza, Cecilia Odonkor, Jason R Pantarotto, Robert MacRae, Graham Cook
Background: The prediction of local recurrence (LR) of stage I non-small cell lung cancer (NSCLC) after definitive stereotactic body radiotherapy (SBRT) remains elusive. The purpose of this study was to assess whether quantitative imaging features on pre-treatment computed tomography (CT) can predict LR beyond 18 (18F) fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT maximum standard uptake value (SUVmax). Methods: This retrospective study evaluated 36 patients with 37 stage I NSCLC who had local tumor control (LC; n=19) and (LR; n=18)...
December 2017: Quantitative Imaging in Medicine and Surgery
https://www.readbyqxmd.com/read/29310420/the-role-of-stereotactic-body-radiation-therapy-in-oligometastatic-colorectal-cancer-clinical-case-report-of-a-long-responder-patient-treated-with-regorafenib-beyond-progression
#9
Michela Roberto, Rosa Falcone, Federica Mazzuca, Livia Archibugi, Nadia Castaldi, Andrea Botticelli, Mattia Falchetto Osti, Paolo Marchetti
RATIONALE: Regorafenib is the new standard third-line therapy in metastatic colorectal cancer (mCRC). However, the reported 1-year overall survival rate does not exceed 25%. PATIENT CONCERNS: A 55-year-old man affected by mCRC, treated with regorafenib combined with stereotactic body radiotherapy (SBRT), showing a durable response. INTERVENTIONS: After 6 months of regorafenib, a PET/CT scan revealed a focal uptake in a solid lung nodule which was treated with SBRT, whereas continuing regorafenib administration...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29299403/radiological-differential-diagnosis-between-fibrosis-and-recurrence-after-stereotactic-body-radiation-therapy-sbrt-in-early-stage-non-small-cell-lung-cancer-nsclc
#10
Rezarta Frakulli, Fabrizio Salvi, Damiano Balestrini, Marcella Palombarini, Ilir Akshija, Silvia Cammelli, Alessio Giuseppe Morganti, Maurizio Zompatori, Giovanni Frezza
Background: Parenchymal changes after stereotactic body radiation therapy (SBRT) make differential diagnosis between treatment outcomes and disease recurrence often difficult. The purpose of our study was to identify the radiographic features detectable at computed tomography (CT) scan [high-risk features (HRFs)] that allow enough specificity and sensitivity for early detection of recurrence. Methods: We retrospectively evaluated patients who underwent SBRT for inoperable early stage non-small cell lung cancer (NSCLC)...
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29290784/systemic-inflammation-biomarkers-predict-survival-in-patients-of-early-stage-non-small-cell-lung-cancer-treated-with-stereotactic-ablative-radiotherapy-a-single-center-experience
#11
Hui Luo, Hong Ge, Yingying Cui, Jiangong Zhang, Ruitai Fan, Anping Zheng, Xiaoli Zheng, Yanan Sun
Background: Increasing evidence indicates a relationship between systemic inflammation and survival following treatment in various tumors. However, the correlation of systematic inflammation with survival after stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer (NSCLC) has not been well established. Patients and methods: We retrospectively analyzed patients with newly diagnosed early stage NSCLC treated with SABR in a single institution from 2011 to 2015. The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and lymphocyte- monocyte ratio (LMR) were calculated as systemic inflammation biomarkers...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29290248/stereotactic-body-radiation-therapy-for-isolated-hilar-and-mediastinal-non-small-cell-lung-cancers
#12
Zachary D Horne, Adam H Richman, Michael J Dohopolski, David A Clump, Steven A Burton, Dwight E Heron
OBJECTIVES: The seminal phase II trial for pulmonary stereotactic body radiation therapy (SBRT) suggested that SBRT to central lesions resulted in unacceptable toxicity. Alternative dose-fractionation schemes have been proposed which may improve safety without compromise of efficacy. We report our institutional outcomes of SBRT for hilar/mediastinal non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: A retrospective review was conducted of patients with NSCLC in a hilar or mediastinal nodal station which was treated with SBRT...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29280445/the-influence-of-health-insurance-policy-on-radiation-oncology-physician-sbrt-sabr-use-practices-a-north-american-survey
#13
Jenny Guo, Hyun Kim, Ingrid Kalchman, Tu D Dan, Tingting Zhan, Maria Werner-Wasik
PURPOSE: European data suggest that 8-fraction stereotactic body radiation therapy (SBRT) regimens may be similar in efficacy with less toxicity than ≤5-fraction SBRT for central lung lesions. However, under current Centers for Medicare and Medicaid Services guidelines, SBRT in the United States (US) is reimbursed for only ≤5 fractions, whereas there are no such restrictions for reimbursement in Canada. We hypothesize that US-specific SBRT reimbursement policies influence the use of ≥5-fraction SBRT in US academic centers in comparison with comparable Canadian centers...
November 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29277565/pilot-study-of-the-safety-and-efficacy-of-dose-escalation-in-stereotactic-body-radiotherapy-for-peripheral-lung-tumors
#14
Takamasa Mitsuyoshi, Yukinori Matsuo, Takashi Shintani, Yusuke Iizuka, Nami Ueki, Mitsuhiro Nakamura, Takashi Mizowaki
BACKGROUND: This pilot study aimed to evaluate the safety and efficacy of a dose escalation method for the treatment of peripheral lung tumors by administrating steep dose gradients in the target volumes via stereotactic body radiotherapy (SBRT). PATIENTS AND METHODS: Patients with peripheral lung tumors were enrolled onto this study and treated with SBRT using a total dose of 70 Gy in 4 fractions at target isocenter, covering the planning target volume surface with 70% of the isodose...
November 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29277249/fine-tuning-the-normal-tissue-objective-in-eclipse-for-lung-stereotactic-body-radiation-therapy
#15
James P Bell, Pretesh Patel, Kristin Higgins, Mark W McDonald, Justin Roper
The purpose of this study was to characterize the effects of the normal tissue objective (NTO) on lung stereotactic body radiation therapy (SBRT) dose distributions. The NTO is a spatially varying constraint used in Eclipse to limit dose to normal tissues by steepening the dose gradient. However, the multitude of potential NTO setting combinations challenges optimal NTO tuning. In the present study, a broad range of NTO settings are investigated for lung SBRT treatment planning with volumetric modulated arc therapy(VMAT)...
December 22, 2017: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
https://www.readbyqxmd.com/read/29275314/radiotherapy-and-tyrosine-kinase-inhibitors-in-stage-iv-non-small-cell-lung-cancer-real-life-experience
#16
Paolo Borghetti, Marco Lorenzo Bonù, Elisa Roca, Sara Pedretti, Emiliano Salah, Anna Baiguini, Diana Greco, Luca Triggiani, Marta Maddalo, Niccolò Giaj Levra, Filippo Alongi, Stefano Maria Magrini, Michela Buglione
AIM: To investigate the role of conventional radiotherapy (RT) and stereotactic body radiotherapy (SBRT) in patients with epidermal growth factor (EGFR)-mutant or anaplastic lymphoma kinase (ALK) rearrangement-positive metastatic non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Fifty patients with EGFR-mutated or ALK rearrangement-positive NSCLC were treated at our Institution. Radiotherapy was delivered before, after or concomitantly with tyrosine kinase inhibitors (TKIs)...
January 2018: In Vivo
https://www.readbyqxmd.com/read/29275308/early-pet-ct-after-stereotactic-radiotherapy-for-stage-1-non-small-cell-lung-carcinoma-is-predictive-of-local-control
#17
Marguerite Tyran, Nathalie Charrier, Julien Darreon, Anne Madroszyk, Agnes Tallet, Naji Salem
BACKGROUND/AIM: Radiological evaluation after stereotactic-body-radiotherapy (SBRT) for non-small-cell lung carcinoma (NSCLC) is often difficult due to lung radiation-induced image modifications on computed tomographic (CT) scan. The aim of this study was to evaluate positron-emission tomography-computed tomography (PET-CT) using fluorodeoxyglucose after SBRT in primary lung cancer. PATIENTS AND METHODS: Eighteen patients with histologically proven NSCLC were treated with SBRT...
January 2018: In Vivo
https://www.readbyqxmd.com/read/29249566/evaluation-of-mlc-leaf-transmission-on-imrt-treatment-plan-quality-of-patients-with-advanced-lung-cancer
#18
Jiayun Chen, Guishan Fu, Minghui Li, Yixin Song, Jianrong Dai, Junjie Miao, Zhiqiang Liu, Yexiong Li
The purpose of this paper was to evaluate the impact of leaf treatment of multileaf collimator (MLC) in plan quality of intensity-modulated radiotherapy (IMRT) of patients with advanced lung cancer. Five MLCs with different leaf transmissions (0.01%, 0.5%, 1.2%, 1.8%, and 3%) were configured for an accelerator in a treatment planning system. Correspondingly, 5 treatment plans with the same optimization setting were created and evaluated quantitatively for each patient (11 patients total) who was diagnosed with advanced lung cancer...
December 14, 2017: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
https://www.readbyqxmd.com/read/29236642/noninvasive-cardiac-radiation-for-ablation-of-ventricular-tachycardia
#19
Phillip S Cuculich, Matthew R Schill, Rojano Kashani, Sasa Mutic, Adam Lang, Daniel Cooper, Mitchell Faddis, Marye Gleva, Amit Noheria, Timothy W Smith, Dennis Hallahan, Yoram Rudy, Clifford G Robinson
BACKGROUND: Recent advances have enabled noninvasive mapping of cardiac arrhythmias with electrocardiographic imaging and noninvasive delivery of precise ablative radiation with stereotactic body radiation therapy (SBRT). We combined these techniques to perform catheter-free, electrophysiology-guided, noninvasive cardiac radioablation for ventricular tachycardia. METHODS: We targeted arrhythmogenic scar regions by combining anatomical imaging with noninvasive electrocardiographic imaging during ventricular tachycardia that was induced by means of an implantable cardioverter-defibrillator (ICD)...
December 14, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29233523/stereotactic-body-radiation-therapy-for-stage-i-non-small-cell-lung-cancer-the-importance-of-treatment-planning-algorithm-and-evaluation-of-a-tumor-control-probability-model
#20
Nitin Ohri, Wolfgang Tomé, Shalom Kalnicki, Madhur Garg
BACKGROUND: Stereotactic body radiation therapy (SBRT) is increasingly used to treat early-stage non-small cell lung cancer (NSCLC). A previous report introduced the term size-adjusted biologically effective dose (sBED), which accounts for tumor diameter and biologically effective dose (BED) and may be used to predict the likelihood of local control following SBRT. Here we seek to replicate those findings using a separate dataset. METHODS AND MATERIALS: We queried the RSSearch Patient Registry for patients treated with SBRT for stage I NSCLC...
October 7, 2017: Practical Radiation Oncology
keyword
keyword
46142
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"